Last reviewed · How we verify
CMAB007
CMAB007 is a monoclonal antibody that targets and inhibits a specific immune checkpoint or tumor-associated antigen to enhance anti-tumor immunity.
At a glance
| Generic name | CMAB007 |
|---|---|
| Also known as | Omalizumab alpha, recombinant humanized anti-IgE monoclonal antibody |
| Sponsor | Taizhou Mabtech Pharmaceutical Co.,Ltd |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
While the exact molecular target of CMAB007 has not been publicly disclosed in detail, it is developed as an immunotherapeutic monoclonal antibody by Taizhou Mabtech Pharmaceutical. As a Phase 3 candidate, it is likely designed to modulate immune responses against cancer cells, potentially through checkpoint inhibition or direct tumor antigen targeting.
Approved indications
Common side effects
Key clinical trials
- Compare the PK, Safety, and Immunogenicity of Process-Changed CMAB007 and Xolair in Healthy Adult Male Subjects (PHASE1)
- To Compare Efficacy and Safety of CMAB007 and Xolair® in Patients With Chronic Spontaneous Urticaria (PHASE3)
- Comparative Study of CMAB015 and Secukinumab for Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD, Safety and Immunogenicity (PHASE1)
- The Study of Omalizumab (CMAB007 and Xolair) in Healthy Subjects to Compare the PK, PD and Safety (PHASE1)
- Anti-IgE Monoclonal Antibody Treatment in Patients With Allergic Asthma. (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CMAB007 CI brief — competitive landscape report
- CMAB007 updates RSS · CI watch RSS
- Taizhou Mabtech Pharmaceutical Co.,Ltd portfolio CI